Dr. Reddy's plaque psoriasis treatment secures US approval
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
The U.S. Food and Drug Administration approved Dr. Reddy's Laboratories Ltd.'s new drug application for Impoyz cream for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older.
Impoyz is licensed to Encore Dermatology Inc. for commercialization of the product in the U.S.
